Immunotherapy for autoimmune diseases is rapidly shifting from a research curiosity to a real clinical option, with treatments like CAR T-cell therapy, B-cell depletion, and low-dose interleukin-2 already showing they can push some patients into drug-free remission. The core idea is to retrain or selectively adjust the immune system rather than simply suppressing it across the board, and the results from early trials have been striking enough to reshape how researchers think about conditions like lupus, rheumatoid arthritis, and multiple sclerosis.
Why Blanket Immunosuppression Is Not Enough
For decades, the standard approach to autoimmune disease has been broad immunosuppression. Drugs like methotrexate, azathioprine, and corticosteroids dial down immune activity generally, which can control symptoms but comes with a long list of problems: higher infection risk, organ damage from the drugs themselves, and the need for ongoing treatment that never actually fixes the underlying misfiring of the immune system. Traditional treatments relieve symptoms but carry serious side effects and do not address the immunological dysfunction driving the disease.1PubMed Central. Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions That gap between symptom control and genuine correction is what the newer immunotherapies are trying to close.
The ideal outcome would be immune tolerance, where the immune system stops attacking the body’s own tissues and the patient no longer needs medication at all. That goal has long seemed unrealistic, but several approaches are now getting closer to it than anyone expected a decade ago.2The Lancet Rheumatology. Immune tolerance in autoimmune disease
CAR T-Cell Therapy and Autoimmune Disease
The most dramatic development has come from borrowing a tool originally built for cancer. CAR T-cell therapy involves removing a patient’s own T cells, genetically engineering them to target a specific marker on other immune cells, and infusing them back. In autoimmune disease, the target is usually CD19, a protein found on B cells. Since B cells produce the autoantibodies that drive diseases like lupus, wiping them out can halt the autoimmune attack at its source.
A landmark series at the University of Erlangen treated patients with lupus, inflammatory myositis, and systemic sclerosis using CD19-targeting CAR T cells. Over a median follow-up of 15 months, every lupus patient achieved full remission, every myositis patient had a major clinical response, and every systemic sclerosis patient saw a meaningful drop in disease activity. All patients were able to stop their immunosuppressive medications entirely.3PubMed. CD19 CAR T-Cell Therapy in Autoimmune Disease – A Case Series with Follow-up The B cells that reappeared months later were naïve, meaning they had not yet learned to attack the body’s own tissues. In an earlier report on lupus patients specifically, those reappearing B cells showed non-class-switched receptors, essentially a fresh start for the B-cell compartment, and drug-free remission held even after B cells returned.4Nature Medicine. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
These results are small in scale, and researchers are careful to note that longer follow-up is needed. But the fact that patients with severe, treatment-resistant disease achieved complete remission without continued drugs was genuinely unexpected. The side effects were manageable: mild cytokine-release syndrome, which is the immune system’s short-term inflammatory reaction to the infused cells, was the main concern.5Nature Medicine. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
B-Cell Depletion With Monoclonal Antibodies
CAR T cells are not the only way to clear out B cells. Monoclonal antibodies that target CD20, a different protein on B-cell surfaces, have been used in autoimmune disease for over two decades. Rituximab was the pioneer, and its apparent success in conditions like multiple sclerosis and neuromyelitis optica led to newer antibodies including ocrelizumab, ofatumumab, ublituximab, and the CD19-targeting antibody inebilizumab. Each depletes B cells effectively, though structural differences between them affect how long the depletion lasts and the safety profile.6PubMed Central. The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function
Unlike CAR T-cell therapy, these antibodies typically require repeated infusions. B cells come back over time, and so does the autoimmune activity in many patients. The treatment manages the disease rather than resetting the immune system. There are also side effects to watch for: increased infection susceptibility is the most common concern, and occasional unusual reactions have been reported. One case documented eruptive skin lesions (pyogenic granulomas) developing after anti-CD20 therapy for rheumatoid arthritis, a reminder that depleting an entire cell population is not without consequences.7PubMed Central. Multiple eruptive periungual pyogenic granulomas during anti-CD20 monoclonal antibody therapy for rheumatoid arthritis
Cytokine-Targeting Therapies
Rather than wiping out entire cell types, another approach goes after the chemical messengers that fuel autoimmune inflammation. Cytokines like tumor necrosis factor alpha (TNF-alpha), interleukin-6, interleukin-17, and interleukin-23 all play distinct roles in driving immune attacks against the body’s own tissues. Antibodies that neutralize these cytokines or block their receptors have become a mainstay of treatment for conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease.8PubMed Central. Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases
TNF-alpha blockers were the first wave and remain widely prescribed. IL-6 inhibitors like tocilizumab followed, and IL-17 and IL-23 blockers have been particularly effective in psoriasis and psoriatic arthritis. These treatments can produce profound symptom relief and slow joint or tissue damage, but they share a limitation with B-cell depletion: they typically need to be continued indefinitely. Stop the drug, and the inflammation often returns. They are also not without risk, as blocking cytokines that play roles in fighting infection can leave patients more vulnerable to certain pathogens.
Low-Dose Interleukin-2 and Regulatory T Cells
One of the more counterintuitive strategies involves giving patients a cytokine that is normally associated with ramping up immune activity. Interleukin-2 (IL-2) at standard doses stimulates killer T cells, which is why it was originally used in cancer treatment. But at very low doses, IL-2 preferentially boosts regulatory T cells (Tregs), the immune cells whose job is to keep the rest of the immune system in check. In autoimmune diseases, Tregs are often deficient or dysfunctional, and low-dose IL-2 aims to restore that balance.9PubMed Central. Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases
In lupus patients, researchers found that the loss of a key surface marker on Tregs was directly tied to insufficient IL-2 production by other T cells. Treating these patients with low-dose IL-2 selectively corrected the Treg defect, expanding the regulatory population without broadly activating the immune system.10Annals of the Rheumatic Diseases. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus The appeal of this approach is its precision: rather than hammering the immune system with suppressive drugs, you are strengthening the body’s own built-in off switch. Low-dose IL-2 also appears to inhibit the differentiation of pro-inflammatory T-cell subsets, adding a second layer of benefit.11PubMed. Low-dose IL-2 therapy in autoimmune diseases: An update review
Beyond natural Tregs, researchers are also engineering regulatory T cells for even more targeted therapy. Tregs can be modified to express specific receptors that guide them to the tissue under attack, such as the pancreas in type 1 diabetes. Strategies include engineering FOXP3 expression to create a larger supply of suppressive cells, equipping Tregs with chimeric antigen receptors for antigen-specific suppression, and improving Treg survival once infused.12PubMed. Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes This work is still largely preclinical, but it represents a step toward immune therapies that suppress only the specific autoimmune response while leaving the rest of the immune system intact.
FcRn Inhibitors for Antibody-Driven Diseases
Some autoimmune diseases are driven primarily by pathogenic antibodies circulating in the blood. In myasthenia gravis, for example, antibodies attack the connection between nerves and muscles, causing progressive weakness. A newer class of drugs targets the neonatal Fc receptor (FcRn), a molecule that normally extends the lifespan of IgG antibodies by recycling them. Block FcRn, and IgG antibodies, including the harmful autoantibodies, get broken down much faster.13PubMed Central. FcRn inhibitors: a novel option for the treatment of myasthenia gravis
This concept has been validated in animal models of myasthenia gravis, where blocking FcRn with a monoclonal antibody reduced both disease severity and the levels of pathogenic antibodies in the blood in a dose-dependent way.14The Journal of Immunology. Amelioration of Experimental Autoimmune Myasthenia Gravis in Rats by Neonatal FcR Blockade FcRn inhibitors like efgartigimod and rozanolixizumab have since moved into human trials and approvals for myasthenia gravis, with interest in expanding to other antibody-mediated conditions. The advantage is that these drugs lower all IgG levels, which works well when the problem is clearly antibody-driven. The trade-off is that protective antibodies get cleared too, temporarily increasing infection risk.
Bispecific Antibodies
Standard monoclonal antibodies hit one target. Bispecific antibodies are engineered to bind two different molecules at once, which opens the door to blocking two disease-driving pathways simultaneously with a single drug. Several have entered clinical trials for autoimmune diseases. Obexelimab, which targets both a B-cell surface marker and an inhibitory receptor, showed promise in a phase II trial for lupus. Other bispecifics have been less successful: lutikizumab failed in osteoarthritis, and romilkimab did not meet its endpoints in idiopathic pulmonary fibrosis.15PubMed. Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date
One active area of research involves bispecific antibodies that simultaneously target BAFF (a protein critical for B-cell survival) and IL-17 (an inflammatory cytokine). Tibulizumab was engineered by fusing an anti-IL-17 fragment onto an anti-BAFF antibody, and it potently blocked both targets in cell and animal models.16PubMed Central. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease A separate team built a similar BAFF/IL-17 bispecific and tested it in a lupus mouse model, where it reduced autoantibody levels, kidney damage, and inflammatory cytokine production in a dose-dependent fashion.17PubMed Central. Design and development of a bispecific antibody targeting BAFF and IL-17 for systemic lupus erythematosus treatment The logic is compelling: autoimmune diseases involve multiple pathways going wrong at once, so hitting two of them simultaneously could be more effective than targeting either alone.
Tolerogenic Vaccines
Perhaps the most ambitious concept in autoimmune immunotherapy is the tolerogenic vaccine, which aims to teach the immune system to stop reacting to a specific self-antigen rather than suppressing the immune response broadly. In a standard vaccine, you present the immune system with a target and provoke an attack. A tolerogenic vaccine presents the same kind of target but in a context that signals “do not attack.”
Researchers working on multiple sclerosis developed a nanoparticle-based tolerogenic vaccine using mesoporous polydopamine particles loaded with myelin-derived antigens. In a mouse model mimicking MS, the vaccine induced tolerogenic dendritic cells that expanded regulatory T cells rather than activating inflammatory ones. The result was reduced infiltration of harmful immune cells into the central nervous system. In early-stage treatment, it prevented disease development; in late-stage treatment, it promoted recovery from complete paralysis.18PubMed. Mesoporous polydopamine nanoparticle-based tolerogenic vaccine induces antigen-specific immune tolerance to prevent and treat autoimmune multiple sclerosis This remains preclinical, but it represents exactly the kind of antigen-specific, drug-free solution that the field is chasing.
Immune Checkpoint Agonists and Stem Cell Transplantation
Immune checkpoints are best known in cancer, where blocking them unleashes the immune system against tumors. In autoimmune disease, the opposite approach is being explored: agonizing (activating) checkpoint molecules to put the brakes on overactive immune responses. This strategy targets the dysregulated T-cell activation that drives autoimmunity while trying to preserve the immune system’s ability to fight infections and cancer.19PubMed. Immune checkpoint molecules beyond PD-1 and CTLA-4: emerging targets in autoimmune diseases and cancer immunotherapy Research is still in early stages, with most work focused on identifying which checkpoint pathways can be safely amplified without overcorrecting into immunodeficiency.
At the extreme end of immune resetting sits autologous hematopoietic stem cell transplantation (AHSCT). The procedure involves harvesting a patient’s stem cells, then using chemotherapy to wipe out the existing immune system before reinfusing the stem cells to rebuild it from scratch. Studies have shown that AHSCT can deplete the autoimmune compartment and generate a new immune repertoire that tolerates the body’s own tissues, leading to long-term remission without ongoing treatment.20PubMed. Resetting the immune response after autologous hematopoietic stem cell transplantation for autoimmune diseases The obvious downside is the severity of the procedure. The chemotherapy required to ablate the immune system carries real risks, including life-threatening infections during the recovery period. AHSCT is generally reserved for patients with severe, refractory disease where the potential benefit justifies the danger.
The Gut Microbiome as an Emerging Target
Increasingly, the immune system’s relationship with gut bacteria is being pulled into the autoimmune immunotherapy conversation. Microbial metabolites like short-chain fatty acids and indole derivatives directly influence regulatory T-cell differentiation and inflammatory pathways. Disruption of the gut microbial community, known as dysbiosis, is consistently associated with autoimmune conditions including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and type 1 diabetes. Interventions like probiotics, prebiotics, and fecal microbiota transplantation are being investigated for their ability to restore microbial and immune balance.21PubMed Central. The Role of Intestinal Microbiota and Immune System Interactions in Autoimmune Diseases
For lupus specifically, emerging evidence suggests that gut dysbiosis contributes to disease severity, and normalizing the microbiota through fecal transplantation may offer a new treatment avenue.22PubMed Central. Systemic lupus erythematosus therapeutic strategy: From immunotherapy to gut microbiota modulation This is early-stage science, and the evidence base is far thinner than for CAR T cells or B-cell depletion. But the microbiome’s role in shaping immune tolerance makes it a natural fit for the broader immunotherapy framework, and it may eventually complement more targeted therapies.
Matching Patients to the Right Therapy
With so many immunotherapy options in development, figuring out which patients will respond to which treatment is becoming a major challenge. Biomarker research aims to predict treatment response before starting therapy, but the field is still catching up. A systematic review evaluating lymphocyte profiling as a predictor of drug response in rheumatoid arthritis, lupus, and primary Sjögren’s syndrome found that while many studies reported promising associations, most could not be independently confirmed. The most consistent finding was a link between pre-treatment levels of memory B cells and response to rituximab, though even that result had some conflicting data.23PubMed. Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?
Despite considerable research into biomarkers that could guide personalized immunotherapy, most have not yet been incorporated into routine clinical practice.24PubMed Central. The role of biomarkers in personalized immunotherapy That means treatment decisions still rely heavily on clinical judgment, trial and error, and the specific disease subtype. Getting this piece right will matter enormously as immunotherapies become more diverse. Two patients with the same autoimmune diagnosis can have very different immunological profiles, and a treatment that resets one patient’s disease might do nothing for another.
When to Intervene
Timing may turn out to be as important as the therapy itself. A life-course approach to pediatric autoimmune disease emphasizes that secondary prevention, meaning identifying preclinical autoimmunity through screening, could allow targeted immunomodulatory therapies to delay or prevent disease onset before symptoms even appear. In children with established disease, early aggressive therapy limits long-term complications.25PubMed Central. From genes to environment: A life-course approach to prevent pediatric autoimmune diseases This principle likely extends to adults as well. Most current immunotherapy trials enroll patients with severe, refractory disease who have failed standard treatments, which is a reasonable starting point for safety reasons. But there is growing recognition that intervening earlier in the disease course, before irreversible tissue damage accumulates, could yield better and more durable outcomes.
Cost and Manufacturing Barriers
The science is moving faster than the infrastructure to deliver it. CAR T-cell therapy is the clearest example: because the treatment uses a patient’s own cells, each dose must be manufactured individually. The patient’s T cells are extracted, genetically modified, expanded in the lab, and then reinfused, a process that can take several weeks. During that manufacturing window, the patient’s disease may progress. The per-patient cost is substantial, running into hundreds of thousands of dollars for existing cancer indications.26ScienceDirect. Review Challenges and opportunities: CAR-T cell therapy in autoimmune diseases – Section: Manufacturing and cost considerations
Off-the-shelf or “allogeneic” CAR T cells, manufactured from donor cells rather than the patient’s own, are one potential solution and are under active development. If they work reliably, they could dramatically cut both production time and cost. Meanwhile, monoclonal antibodies and cytokine therapies are already manufactured at scale and cost far less, which is one reason B-cell depletion with drugs like rituximab remains the practical workhorse for many autoimmune conditions even as more advanced therapies emerge. The tension between what is scientifically possible and what is logistically deliverable will shape which immunotherapies actually reach patients over the coming decade.
Immunotherapy Side Effects in Autoimmune Disease
A persistent irony in this field is that immunotherapy can sometimes trigger new autoimmune problems. This is most visible in cancer immunotherapy, where checkpoint inhibitors designed to unleash the immune system against tumors frequently cause immune-related adverse events that look a lot like autoimmune diseases. When immunotherapy is used to treat autoimmune disease, the safety considerations are different but still real. CAR T-cell therapy brings cytokine-release syndrome and the risk of prolonged B-cell depletion leaving patients vulnerable to infections. B-cell-depleting antibodies carry similar infection risks over time. FcRn inhibitors lower all protective antibodies along with the pathogenic ones. Even low-dose IL-2, which aims to be precision medicine, has a narrow therapeutic window where slightly higher doses could activate the wrong T-cell populations.27PubMed Central. The dark side of immunotherapy
Each approach trades one set of risks for another, and the field is still learning where those trade-offs land in practice. For patients with severe disease who have exhausted conventional options, accepting short-term risk for the chance of long-term drug-free remission makes intuitive sense. For patients with milder disease, the calculus is harder. The long-term safety data for most of these newer immunotherapies in autoimmune populations simply does not exist yet, which is why most remain restricted to clinical trials or compassionate-use settings for now.